CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Abstract Currently, there is still a lack of novel and effective drug targets to improve the prognosis of hepatocellular carcinoma (HCC). Additionally, the role of CHEK2 in HCC has not been reported yet. The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD1...
Main Authors: | Yuyan Chen, Zhengyi Zhu, Xingyu Wu, Hui Li, Wenxian Guan, Haozhen Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-01-01
|
Series: | Cell Death Discovery |
Online Access: | https://doi.org/10.1038/s41420-023-01777-4 |
Similar Items
-
Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico
by: Leonardo S Lino-Silva, et al.
Published: (2022-02-01) -
TP53 mutation‐related senescence is an indicator of hepatocellular carcinoma patient outcomes from multiomics profiles
by: Yu‐Yan Chen, et al.
Published: (2023-05-01) -
Systematic profiling of a lipid metabolism‐derived signature guides risk‐stratification and therapeutic strategies in hepatocellular carcinoma
by: Zhengyi Zhu, et al.
Published: (2023-05-01) -
TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma
by: Yong Li, et al.
Published: (2022-12-01) -
TP53 Mutations in Esophageal Squamous Cell Carcinoma
by: Leqi Zhong, et al.
Published: (2023-09-01)